Interferon Responses after Vaccine Administration
A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Pathogens-host Immune Interface".
Deadline for manuscript submissions: closed (31 July 2024) | Viewed by 6725
Special Issue Editors
Interests: primary immunodeficiencies/inborn errors of immunity; newborn screening; severe combined immunodeficiency; interferonopathy
Special Issue Information
Dear Colleagues,
Interferons (IFNs) are a family of proteins that cells exhibiting productive effects in response to infection or other stressors. They play a critical role in immune responses by activating antiviral defenses, stimulating the production of antibodies, and recruiting immune cells to the site of infection.
The role of IFNs in the immune response to vaccines is becoming increasingly recognized. IFNs can enhance the production of antibodies and other immune responses to vaccines, and they can also help to protect against vaccine-preventable diseases.
The articles in this Special Issue will explore the latest research on the role of IFNs in the immune response to vaccines. They will discuss how IFNs interact with other components of the immune system, how IFNs can be used to improve the efficacy of vaccines, and the safety and efficacy of IFNs in vaccine development.
This special issue will be of interest to researchers and clinicians working in the fields of immunology, vaccinology, and infectious diseases.
Dr. Luis Ignacio González-Granado
Dr. Hugh Thomson Reyburn
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- interferon response
- cytokine signaling
- antiviral defense
- innate immunity
- adaptive immunity
- antibodies anti-Interferon
- primary Immunodeficiencies/inborn errors of immunity
- host defense mechanisms
- immunotherapy
- vaccine efficacy
- interferon type I/III
- interferon type II
- immunogenicity
- interferonopathy
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue policies can be found here.
